Filing identity and reporting period
Important identity discrepancy: The supplied filing is a Form 10-Q for Gold Swap Inc., not Silo Pharma, Inc. It covers the quarter ended September 30, 2012; the financial statements are unaudited. The filing describes Gold Swap as a development-stage company planning to procure and recycle precious metals and second-hand jewelry.
Financial results and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | None | None |
| General and administrative expense / net loss, 2012 | $8,550 | $27,257 |
| General and administrative expense / net loss, 2011 | $17,719 | $43,470 |
| Net cash used in operating activities, 2012 | Not separately reported | $16,473 |
| Net cash used in operating activities, 2011 | Not separately reported | $39,970 |
Expenses and losses declined year over year, mainly because the prior-year periods included professional fees related to the S-1 filing process. The company reported no revenue since inception, so revenue growth and operating margins are not applicable. Interest expense was not reported for the periods shown.
At September 30, 2012, cash was $279, total assets $279, current liabilities $14,284, notes payable $15,000, and total liabilities $29,284. Working capital was negative $14,005 and stockholders’ deficit was $29,005. Cash decreased by $1,473 during the first nine months, from $1,752 at year-end 2011. Financing provided $15,000, from notes payable, during the period. No capital expenditures or off-balance-sheet arrangements were reported.
Material changes, outlook, and risks
- Compared with the first nine months of 2011, net loss narrowed by $16,213 and operating cash use declined by $23,497. Cash on hand nevertheless fell to $279.
- Five notes, each originally $3,000, bear 6% interest, carry a 12% default rate, are unsecured, and were amended to mature February 25, 2014. One lender is related by marriage to the CEO.
- Management planned to arrange refinery agreements, solicit consumers selling precious-metal items, and earn a spread between scrap and spot prices. The company said it had not met its proposed timetable and lacked sufficient funds to execute its plans for the next 12 months.
- Management said officers and directors had orally agreed to cover operating expenses or lend funds if needed, but they had no legal or contractual obligation to do so. Additional financing was uncertain.
- The filing raises substantial going-concern uncertainty: the company had no revenue, a working-capital and stockholders’ deficit, and depended on commencing operations and potentially obtaining related-party financing. The statements contain no adjustments that might be required if it could not continue as a going concern.
- The filing reports no pending material legal proceedings. Management stated disclosure controls were effective and reported no material changes in internal control over financial reporting.
Most important facts to verify
- Confirm the intended issuer: the provided filing identifies Gold Swap Inc., not Silo Pharma, Inc.
- Verify the filing and period against the SEC record, including the issuer’s name and reporting date.
- Review the note agreements, accrued interest, maturity terms, and the nature and extent of any related-party financing commitments.
- Assess available funding and the company’s ability to commence operations given $279 of cash and its disclosed going-concern uncertainty.
- Verify the status of refinery arrangements, operating plans, and any subsequent events or financing not included in the supplied text.